U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06837961) titled 'LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases' on Feb. 17.
Brief Summary: The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing clinical symptoms of upper respiratory infectious diseases in healthy adults. Researchers will compare LC-Plasma to placebo, participants will take a tablet containing LC-Plasma or placebo daily for 4 weeks.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunt...